ESTRO 35 2016 S315 ________________________________________________________________________________ investigate which parameters were related to the patients' opinion about cosmesis. In addition, we analyzed whether firmness, presence of rib pain or quality of life (QoL) aspects (EORTC QLQ C-30 questionnaire) at 4 years were related to the patients' opinion on cosmetic outcome.
Material and Methods:
Patients affected by oligometastatic breast cancer were enrolled in this phase II trial. Inclusion criteria were the following: 1) histologically confirmed diagnosis of breast cancer, 2) 5 or fewer metastatic lesions, 3) no brain metastases, 4) primary tumor controlled. Radiotherapeutic treatment was SBRT (30-45 Gy in 3 fractions) or fractionated IMRT (40-60 Gy in 15-25 fractions). Primary endpoint was PFS; secondary endpoints were localcontrol (LC), overall survival (OS), and toxicity, which was assessed using the CTCAE v4.0 scale.
Results:
The analysis was conducted on 37 patients. The median age was 55 years. Twenty-five (68%) had oligometastatic disease at diagnosis, and 12 (32%) had the oligometastatic status induced by systemic treatment. Sixteen (43%) patients had a single metastasis, and 21 (47%) had 2 or more lesions. Thirty-one (84%) patients were treated with SBRT and 6 (16%) with fractionated IMRT. With a median follow-up of 18 months, 1-year and 2-year PFS was 74% and 44%, respectively. No differences was seen in PFS between patients with only 1 metastases vs. those with ≥2 metastases, or between patients treated with SBRT vs. fractionated IMRT. Only two patients experienced local failure. One of these two patients had an isolated local failure for a spinal lesion that was treated with a minimum dose of 17 Gy in 3 fractions (being the spinal cord constraint prior on the PTV coverage). Two-year LC was 96%. Two patients died of disease, and 2year OS was 96%. The proposed treatment was well tolerated; no Grade ≥3 toxicity was documented. Two patients experienced Grade 2 pain, 4 Grade 1 pain, and 2 developed Grade 2 fatigue.
Conclusion:
Radical radiotherapy delivered to all the metastatic sites in oligometastatic breast cancer patients led to promising results in terms of local control and progressionfree survival. Treatment was well tolerated. The results of this study may motivate for conducting phase III trials.
PO-0676
Impact of IMN irradiation on the right coronary artery and OAR in right-sided post-mastectomy patients K. Rock Purpose or Objective: Previous studies have shown an increased risk of ischemic heart disease in breast cancer patients treated with radiotherapy (RT). It has recently been reported that the risk of major coronary events increases per gray of mean radiation dose delivered to the heart for patients undergoing either left-or right-sided breast RT. However, the anatomy of cardiovascular damage related to right-sided breast RT has not been well-described, specifically for radiation dose delivered to the right coronary artery (RCA). This may be of particular relevance for regional nodal irradiation that includes the internal mammary nodes (IMNs). In this prospective planning study, the impact of IMN irradiation on the RCA and organs at risk (OAR) in patients undergoing right-sided post-mastectomy RT (PMRT) was assessed.
Material and Methods:
CT simulation scans of 60 right-sided post-mastectomy patients were identified from an institutional database. In 30 cases, the IMNs were contoured from the 1st to 3rd intercostal space with a PTV of 5 mm. The RCA, heart, lungs and contralateral breast were delineated as OARs. A four-field modified wide tangent photon plan was created encompassing the chestwall, IMNs, supraclavicular fossa and axilla. For the remaining 30 patients (control group), a four-field plan that excluded the IMNs was generated. All patients were planned to receive 50 Gy in 25 fractions over 5 weeks. Doses were compared between the two groups utilizing the Mann-Whitney test to determine whether there was a statistically significant difference in dose to OARs between these groups.
Results:
In the group with IMN treatment, 95% of prescribed dose to the IMN PTV covered a median volume of 99% (range 90-100). There was a significant increase in dose to the RCA in the IMN treated group compared to the control group. The maximum dose to the RCA (3.33 Gy vs 2.35 Gy, p<0.0001) and mean RCA dose (2.41 Gy vs 1.69 Gy, p<0.0001) were both increased. Similarly, the mean heart dose (MHD) was increased (1.3 Gy vs 1.09 Gy, p<0.022). Inclusion of the IMNs increased lung V20 (18 Gy vs 15 Gy, p<0.00021) and mean lung dose (9.1 Gy vs 8.09 Gy, p<0.00051). There was a significant increase in the volume of contralateral breast receiving 3 Gy in the group requiring IMN treatment (3.75 Gy vs 0 Gy, p<0.0001).
Conclusion: Inclusion of the IMNs in patients undergoing
PMRT significantly increases radiation dose to the RCA and MHD. An acceptable dose to the RCA has not been wellestablished but should be as low as is reasonably achievable. The dose and clinical implications of radiation to the RCA needs further evaluation in prospective studies utilizing techniques to minimize cardiac exposure.
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Comparing detailed cardiac structure dose-volume metrics in supine versus prone breast irradiation C. Luo
